TD Private Client Wealth LLC Purchases 81 Shares of iShares Biotechnology ETF (NASDAQ:IBB)

TD Private Client Wealth LLC increased its position in shares of iShares Biotechnology ETF (NASDAQ:IBB) by 3.0% in the fourth quarter, HoldingsChannel reports. The firm owned 2,746 shares of the financial services provider’s stock after purchasing an additional 81 shares during the period. TD Private Client Wealth LLC’s holdings in iShares Biotechnology ETF were worth $363,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in IBB. National Bank of Canada FI boosted its holdings in shares of iShares Biotechnology ETF by 5.9% in the 3rd quarter. National Bank of Canada FI now owns 4,124 shares of the financial services provider’s stock worth $600,000 after acquiring an additional 229 shares in the last quarter. IFP Advisors Inc raised its position in iShares Biotechnology ETF by 237.1% in the 4th quarter. IFP Advisors Inc now owns 16,018 shares of the financial services provider’s stock valued at $2,118,000 after purchasing an additional 11,266 shares during the last quarter. Healthcare of Ontario Pension Plan Trust Fund boosted its stake in iShares Biotechnology ETF by 32.9% in the third quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 663,000 shares of the financial services provider’s stock worth $96,533,000 after purchasing an additional 164,000 shares in the last quarter. Main Management ETF Advisors LLC grew its holdings in shares of iShares Biotechnology ETF by 2.5% during the third quarter. Main Management ETF Advisors LLC now owns 593,370 shares of the financial services provider’s stock worth $86,395,000 after purchasing an additional 14,535 shares during the last quarter. Finally, Cullen Frost Bankers Inc. increased its stake in shares of iShares Biotechnology ETF by 1.5% in the fourth quarter. Cullen Frost Bankers Inc. now owns 5,654 shares of the financial services provider’s stock valued at $748,000 after buying an additional 82 shares in the last quarter. 62.45% of the stock is owned by institutional investors.

iShares Biotechnology ETF Stock Up 1.3 %

Shares of NASDAQ IBB opened at $135.31 on Tuesday. iShares Biotechnology ETF has a 12-month low of $123.60 and a 12-month high of $150.57. The firm’s 50-day simple moving average is $136.25 and its 200 day simple moving average is $139.23. The company has a market cap of $6.39 billion, a price-to-earnings ratio of 27.83 and a beta of 0.84.

iShares Biotechnology ETF Increases Dividend

The business also recently announced a dividend, which was paid on Friday, March 21st. Stockholders of record on Tuesday, March 18th were given a dividend of $0.1212 per share. This is a positive change from iShares Biotechnology ETF’s previous dividend of $0.06. The ex-dividend date was Tuesday, March 18th.

About iShares Biotechnology ETF

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.